Role of Postoperative Radiotherapy on High-Risk Stage pII-IA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study

被引:2
|
作者
Chen, Zu Yi [1 ]
Liang, Huan Wei [2 ]
Liu, Yang [2 ]
Huang, Wei [2 ]
Pan, Xin Bin [2 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Canc Hosp, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Med Univ, Canc Hosp, Dept Radiat Oncol, Nanning 530021, Guangxi, Peoples R China
基金
英国科研创新办公室;
关键词
Non-small cell lung cancer; Stage pIIIA-N2; Lymph node ratio; Postoperative radiotherapy; VINORELBINE PLUS CISPLATIN; LYMPH-NODE RATIO; PHASE-III; SURVIVAL; RADIATION; CONCURRENT; MANAGEMENT; THERAPY; SURGERY; MODELS;
D O I
10.14740/wjon1832
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of the study was to assess the effectiveness of postoperative radiotherapy in high -risk patients with stage pIIIA-N2 non -small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy. Methods: Data from NSCLC patients within the Surveillance, Epidemiology, and End Results (SEER) database were analyzed. The study examined the association between lymph node ratio (LNR) and both cancer -specific survival (CSS) and overall survival (OS) using restricted cubic spline curves. Patients were categorized into highand low -risk groups based on established LNR cut-off values, and survival outcomes were compared between those receiving postoperative radiotherapy and those who did not within the high -risk group. Results: The study included 1,690 patients. An LNR threshold of 0.29 was identified for both CSS and OS. Patients with an LNR > 0.29 demonstrated significantly worse CSS (hazard ratio (HR) = 1.56, 95% confidence interval (CI): 1.37 - 1.78; P < 0.001) and OS (HR = 1.44, 95% CI: 1.28 - 1.62; P < 0.001) compared to those with an LNR < 0.29. In the high -risk group (LNR >= 0.29), postoperative radiotherapy did not significantly affect CSS (HR = 0.98, 95% CI: 0.82 - 1.17; P = 0.809) or OS (HR = 0.95, 95% CI: 0.81 - 1.11; P = 0.533). Conclusions: LNR is a significant prognostic factor in patients with stage pIIIA-N2 NSCLC post complete resection and adjuvant chemotherapy. A higher LNR (> 0.29) is associated with poorer CSS and OS. However, postoperative radiotherapy does not confer survival benefits in these high -risk patients. Our findings suggest that postoperative radiotherapy should not be routinely performed in this subgroup. Further research is required to explore effective treatment strategies for these patients.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [21] Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center
    Zhu, Yixiang
    Zhai, Xiaoyu
    Chen, Sipeng
    Wang, Ziping
    THORACIC CANCER, 2016, 7 (04) : 399 - 405
  • [23] Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer
    Zhai, Wenyu
    Duan, Fangfang
    Li, Dongxia
    Yan, Qihang
    Dai, Shuqin
    Zhang, Bei
    Wang, Junye
    EJSO, 2022, 48 (04): : 752 - 760
  • [24] Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer
    Selek, Ugur
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : 1394 - 1397
  • [25] Effectiveness of Postoperative or Preoperative Radiotherapy on Prognosis in Patients with Stage II Resectable Non-Small Cell Lung Cancer: A Retrospective Study Based on the SEER Database
    Chen, Deng
    Yu, Jinming
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [26] A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer
    Zhang, Chen -Chen
    Yu, Wen
    Zhang, Qin
    Cai, Xu-Wei
    Feng, Wen
    Fu, Xiao-Long
    RADIOTHERAPY AND ONCOLOGY, 2022, 173 : 313 - 318
  • [27] Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter, Thomas P.
    Sebastian, Benni
    Bischof, Marc
    Kugler, Gudrun
    Fischer, Juergen R.
    Schneider, Thomas
    THORACIC AND CARDIOVASCULAR SURGEON, 2016, 64 (06) : 501 - 506
  • [28] Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection
    Xu, Ya-Ping
    Li, Bo
    Xu, Xiao-Ling
    Mao, Wei-Min
    MEDICINE, 2015, 94 (23) : e879
  • [29] Meta-analysis of the efficacy of postoperative adjuvant chemotherapy for stage IB non-small cell lung cancer
    Liu, Siqi
    Wan, Sha
    Feng, Jinghui
    Pang, Yaqi
    Wang, Haiqing
    Zeng, Hui
    Xu, Xinhua
    MEDICINE, 2024, 103 (01) : E36839
  • [30] RISK FACTORS FOR RECURRENCE AFTER PATHOLOGICAL STAGE IA NON-SMALL CELL LUNG CANCER RESECTION
    Otani, Yoshimi
    Shomura, Hiroki
    Toyoshima, Yujiro
    Ishida, Kensuke
    Nishigaki, Yutaka
    Akiba, Yuji
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S830 - S831